Fertifa responds to British Fertility Society (BFS) announcement to suspend fertility treatments due to COVID-19
Responding to the BFS’s announcement outlining the impact of COVID-19 on fertility treatment, Fertifa’s Founder Tony Chen said: “We are fully supportive of The BFS’s approach and the guidance it is giving to patients in these unprecedented times. We will continue monitoring given rapidly changing development.”
Tony continued “We also acknowledge that this will be an extremely difficult time for patients who are currently undergoing – or are about to embark upon – fertility treatment, which can be a hugely stressful emotional, wellbeing and financial burden for many, even in times of relative certainty. We’d strongly encourage anyone who is feeling concerned about their situation/any employer who believes their employees are concerned by the situation to look at the options that are available for advice, education and wellbeing support…
Fertifa’s Chief Medical Director Dr Gedis Grudzinskas also commented: “In the foreseeable future, Telehealth can play a vital role for all of us. For any appointments about your health and wellbeing as well as diagnostics testings, we recommend booking a telehealth appointment to limit the risk of exposure.
We strive to improve access to education through our COVID-19, fertility, and workplace series, and enhance network of fertility and wellbeing experts who you can speak with from your own home about what this means for you and your family.
Your first appointment with Fertifa is complimentary. You will also have access to 24/7 messaging service, education, at-home female hormone testing kit and at-home male sperm testing kit, all tailored to your individual needs via the Fertifa platform. A nurse will also be handholding you as a single point of contact throughout your journey. E-mail firstname.lastname@example.org to find out more.
The full statement from the BFS can be found here: bit.ly/2UDAqn0